### **SUBSCRIBE**



IPO Note 2025

### **Company Overview**

Indogulf Cropsciences Ltd., established in 1993, is a leading player in India's agrochemical industry, engaged in the manufacturing and marketing of crop protection products, plant nutrients, and biologicals. The company operates under three key business verticals - crop protection, plant nutrients, and biologicals - serving both retail and institutional customers with a focus on enhancing crop yield and promoting sustainable agriculture. The company manufactures a wide range of products across multiple formulations, including water dispersible granules (WDG), suspension concentrate (SC), capsule suspension (CS), ultra-low volume (ULV), emulsion in water (EW), soluble granule (SG), flowable suspension (FS), etc, which are offered in powder, granular, and liquid forms. The company is among the few indigenous manufacturers of technical-grade molecules, such as Spiromesifen and Pyrazosulfuron-ethyl, in India. It exports to over 34 countries and is recognized as a 'Two Star Export House' by the Government of India. Indogulf's registered product portfolio includes insecticides, herbicides, fungicides, plant growth regulators, and bio-stimulants under brand names such as Farrate, Dominator, Corsa-808, Alkazar, Bound Off, Breeza, Apache, and Root-o-Max Gold. Its licensed plant nutrient products include Picaso Gold, Jagromin-99, and Zinc Super+, With four ISO-certified manufacturing facilities across Harvana and Jammu & Kashmir, the company supports production through a robust supply network and strategic sourcing of raw materials from both domestic and global partners. They also provide contract manufacturing services that are customizable to meet specific requirements and formulations requested by its clients, delivering tailored solutions. The company's longevity in the industry, spanning over three decades, is a testament to its ability to adapt to evolving industry landscapes, business environments, and customer requirements. They have built longstanding relationships with numerous customers and catered to major domestic and international brands. Its extensive marketing and distribution network spans 22 states and 3 Union Territories in India, supported by 5,772 domestic distributors, 169 institutional clients, and 129 overseas partners. The company also emphasizes R&D through its NABL-certified laboratory in Haryana, which is backed by a team of scientists and agronomists. The company's R&D efforts have resulted in the grant of three patents since FY19 and two additional patent applications are currently in the pipeline.

$\circ$			4.1	
( )h	IACTO	$\circ$	tha	ICCLIA
$\mathbf{v}$	ICCLO	OI.	LIIC	issue

The net proceeds from the fresh issue will be used towards the following purposes:

- ⇒ Funding working capital requirements of company;
- ⇒ Repayment/Prepayment of a portion of certain outstanding borrowings;
- ⇒ General corporate purposes.

#### **Investment Rationale**

### Diversified product portfolio and specialized products to aid financial performance

The company has diversified its product portfolio over three decades and has grown into a multiproduct manufacturer of crop protection, plant nutrients, and biologicals in India. The company's product portfolio has expanded from 198 products in FY22 to 259 products in FY24, comprising products manufactured using in-house innovative processes, which enables the company to cater to a broad customer base across both domestic and international markets. The company offers a variety of formulations, including WDG, SC, CS, ULV, EW, SG, and FS, available in powder, granular, and liquid forms, along with innovative QR-code-enabled packaging that enhances transparency and product traceability. Indogulf has developed patented packaging solutions, holding three packaging patents alongside 167 trademarks, seven copyrights, and six design registrations, which collectively strengthen brand identity and enhance customer trust. The company also has a robust pipeline, with 152 products under registration and 19 under manufacturing, indicating strong future growth visibility. Its multipurpose manufacturing facilities offer operational flexibility, enabling the company to adjust its product mix according to market demand and reduce its reliance on specific products. Moreover, the agrochemical sector's high regulatory entry barriers, including extensive R&D, long lead times, and complex approvals, further strengthen the company's competitive positioning, making it well-placed to scale operations, maintain customer loyalty, and sustain long-term growth visibility.

# Backward integration and flexible manufacturing infrastructure provides competitive advantage

The company possesses a well-established, backward-integrated manufacturing infrastructure, which forms a critical component of its operational efficiency and cost leadership. The company has four

Issue Details	
Offer Period	26 <sup>th</sup> June, 2025 - 30 <sup>th</sup> June, 2025
Price Band	Rs. 105 to Rs. 111
Bid Lot	135
Listing	BSE, NSE
Issue Size (no. of shares in mn)	18
Issue Size (Rs. in bn)	2
Face Value (Rs.)	10
Issue Structure	•
QIB	50%
NIB	35%
Retail	15%

Systemati	
Corporate Services	BRLM
Ltd	

Registrar	Bigshare Services		
Registiai	Private Ltd.		

Particulars	Pre Issue %	Post Issue %
Promoter & Promoter Group	96.8	69.1
Public	3.2	30.9
Total	100.0	100.0

(Assuming issue subscribed at higher band)

Research Team - 022-61596138

ISO 9001:2015 and ISO 14001:2015 certified facilities spread across approximately 20 acres in Jammu & Kashmir and Haryana. The company has integrated both formulation and technical manufacturing capabilities, along with fertilizer production, allowing it to maintain stringent control over product quality and production timelines. Indogulf's backward integration model enables the in-house manufacturing of key raw materials for select products, significantly reducing reliance on third-party suppliers and import dependencies. This not only minimizes exposure to global supply chain disruptions but also reduces procurement and logistics costs, thereby improving overall operating margins. The backward integration commenced at the Samba facility in November 2006 and later at Nathupur-II in December 2013, marking a long-standing commitment to self-reliance and cost optimization. Notably, captive consumption accounted for 29.5%, 17%, 37%, and 26% of total production in 9MFY25, FY24, FY23, and FY22, respectively, underscoring operational self-sufficiency. The company has also built strong and long-standing relationships with both domestic and international raw material vendors, further ensuring consistent supply, timely delivery, and production continuity. In addition, Indogulf's facilities are multi-purpose and designed to allow for a high level of flexibility, enabling the manufacture of a diverse range of products across all three verticals. This flexibility enables the modification and customization of product portfolios to meet the evolving needs of customers.

### **Valuation**

Indogulf Cropsciences Limited is strategically positioned in the agrochemical sector, with a strong foundation built on a diversified product portfolio, backward-integrated manufacturing, and a robust distribution network. To capitalize on the opportunities, the company has laid out a well-defined growth strategy. This includes expanding its product portfolio and manufacturing capacities, particularly through the proposed in-house dry flowable (DF) plant at Barwasni. It also aims to strengthen its global footprint by increasing export registrations and entering new international markets. Additionally, Indoquif plans to deepen its R&D focus, streamline operations for cost efficiency, and enhance its sales and distribution network across both domestic and overseas territories. This multi-pronged strategy positions the company well for sustainable growth and value creation in the medium to long term. The agrochemical industry is also expected to benefit from structural growth factors, including rising food demand, increasing farm mechanization, and supportive government policies aimed at agricultural sustainability and food security. These trends create a favourable demand environment for Indogulf's wide range of technical, formulation, and fertilizer products. On the financial front, the company has demonstrated stable and improving performance over the past three years, driven by strong demand across both domestic and international markets. EBITDA margins have remained steady, aided by cost optimization and value-added product offerings. The company also maintains a low debt-to-equity, underscoring a strong balance sheet. Overall, Indogulf's financial outlook appears stable and growth-oriented, led by a strong growth trajectory, financial stability, and a well-articulated expansion strategy. The company's backward-integrated manufacturing setup, diversified product portfolio, and expanding global footprint provide a strong competitive advantage. The planned capacity expansion, deeper market penetration, and R&D focus are likely to enhance earnings visibility in the coming years. The issue is valued at a P/E ratio of 21.8x on the upper price band based on FY25 earnings (annualized). We, thus, recommend a "SUBSCRIBE" rating for this issue.

### **Key Risks**

- ⇒ The company is subject to regular inspections and audits, and the success and wide acceptance of its products are largely dependent on quality controls and standards. Any failure to comply with quality standards may adversely affect business prospects and financial performance, including the cancellation of existing and future orders, which may expose the company to warranty claims.
- ⇒ The value of the company's brands may be diluted if there is a change in the brand name for a known product, quality concern, or adverse publicity, which could adversely affect business, financial condition and results of operations.
- ⇒ Underutilization of manufacturing capacities and an inability to effectively utilize expanded manufacturing capacities could harm business prospects and financial performance.

### Income Statement (Rs. in millions)

Particulars	FY22	FY23	FY24	9MFY25
Revenue				
Revenue from Operations	4,872	5,497	5,522	4,642
Total Revenue	4,872	5,497	5,522	4,642
Expenses				
Cost of raw materials consumed	3,063	4,184	4,027	3,180
Purchases of stock-in-trade	498	215	152	94
Changes in inventories of stock-in-trade and finished goods	45	-321	-232	127
Employee benefit expenses	298	349	389	346
Other expenses	497	580	593	459
Total Operating Expenses	4,400	5,008	4,928	4,205
EBITDA	472	489	594	436
Depreciation and Amortization expenses	86	96	103	71
Other income	30	25	36	21
EBIT	1	2	-37	13
Finance costs	117	123	102	106
Exceptional Item	60	116	129	104
РВТ	356	303	360	294
Total tax	93	79	78	77
PAT	264	224	282	217
Diluted EPS	11.2	9.5	11.9	5.1

Source: RHP, BP Equities Research

### **Cash Flow Statement (Rs. in millions)**

Particulars	FY22	FY23	FY24	9MFY25
Cash Flow from operating activities	(70)	(570)	533	(188)
Cash flow from investing activities	(100)	(193)	(52)	(296)
Cash flow from financing activities	161	752	(489)	526
Net increase/(decrease) in cash and cash equivalents	(9)	(11)	(8)	42
Cash and cash equivalents at the beginning of the period	57	48	37	29
Cash and cash equivalents at the end of the period	48	37	29	72
Source: RHP_RP Fouities Research				

Source: RHP, BP Equities Research

## Balance Sheet (Rs. in millions)

	EV22		EV24	OMENOS
Particulars Appets	FY22	FY23	FY24	9MFY25
Assets Non-Current Assets				
	F0F	606	200	274
Property, Plant and Equipment	505	626	390	374
Capital work -in- Progress	90	74	222	484
Investment Property	8 14	0 10	0 44	0 40
Intangible assets Intangible assets under development	7	19	9	15
Right-of-use assets	52	53	41	34
Other financial assets	6	7	6	7
Other infancial assets Other non-current assets	127	65	72	80
	95		109	76
Current tax assets (net)  Total non-current Assets	904	107 <b>961</b>	893	1,11 <b>0</b>
Inventory	1,518	2,091	1,952	
Trade Receivables	1,416	1,765	2,214	2,102 2,282
	1,410	37	2,214	72
Cash and cash equivalents  Other Financial assets	3	6	71	102
Current Tax Assets (Net)	0	0	0	0
Other current assets	247	308	256	302
Total Current Assets	3,232			
Assets Held for Sale	<b>3,232</b>	<b>4,206</b> 8	<b>4,522</b> 8	<b>4,859</b> 8
Total Assets	4,136	5, <b>175</b>	5,422	5,978
Equity	4,130	3,173	3,422	3,370
a) Equity Share Capital	235	235	235	488
b) Other Equity	1,570	1,797	2,081	2,166
Total Equity	1,805	2,032	2,001 <b>2,317</b>	2,100 <b>2,654</b>
Liabilities	1,000	2,002	2,517	2,004
Non-current liabilities				
Borrowings	138	219	186	303
Lease Liabilities	45	45	36	31
Other financial liabilities	58	64	73	84
Provisions	20	20	21	23
Deferred tax liabilities (Net)	-10	-10	-22	-20
Total Non-current Liabilities	251	337	-22 <b>294</b>	-20 <b>422</b>
Financial Liabilities	201	<b>33</b> 1	207	744
Borrowings	876	1,673	1,360	1,760
Trade payables	1,011	818	1,097	834
Lease Liabilities	8	13	9	6
Others	951	768	818	581
Other financial liabilities	67	199	208	195
Provisions	8	9	9	75
Current tax liabilities	95	80	108	20
Other current liabilities	14	14	108	11
Total Current Liabilities	2,080	2,805	2,812	2,902
Total Equity and liabilities	4,136	5,175	5,422	5,978

Source: RHP, BP Equities Research

Institutional Research

Research Desk Tel: +91 22 61596138

Institutional Sales Desk Tel: +91 22 61596403/04

### **Disclaimer Appendix**

Analyst (s) holding in the Stock: Nil

#### **Analyst (s) Certification:**

We analysts and the authors of this report, hereby certify that all of the views expressed in this research report accurately reflect our personal views about any and all of the subject issuer (s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation (s) or view (s) in this report. Analysts aren't registered as research analysts by FINRA and might not be an associated person of the BP Equities Pvt. Ltd. (Institutional Equities).

#### **General Disclaimer**

This report has been prepared by the research department of BP EQUITIES Pvt. Ltd, is for information purposes only. This report is not construed as an offer to sell or the solicitation of an offer to buy or sell any security in any jurisdiction where such an offer or solicitation would be illegal.

BP EQUITIES Pvt. Ltd have exercised due diligence in checking the correctness and authenticity of the information contained herein, so far as it relates to current and historical information, but do not guarantee its accuracy or completeness. The opinions expressed are our current opinions as of the date appearing in the material and may be subject to change from time to time. Prospective investors are cautioned that any forward looking statement are not predictions and are subject to change without prior notice.

Recipients of this material should rely on their own investigations and take their own professional advice. BP EQUITIES Pvt. Ltd or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. BP EQUITIES Pvt. Ltd. or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

BP EQUITIES Pvt. Ltd and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. Opinions expressed are our current opinions as of the date appearing on this material only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by any person in any locality, state and country or other jurisdiction where such distribution, publication or use would be contrary to the law or regulation or would subject to BP EQUITIES Pvt. Ltd or any of its affiliates to any registration or licensing requirement within such jurisdiction.

### **Corporate Office:**

4th floor, Rustom Bldg, 29, Veer Nariman Road, Fort, Mumbai-400001 Phone- +91 22 6159 6464 Fax-+91 22 6159 6160 Website- www.bpwealth.com Registered Office:

24/26, 1st Floor, Cama Building, Dalal street, Fort, Mumbai-400001

BP Wealth Management Pvt. Ltd. CIN No: U67190MH2005PTC154591

BP Equities Pvt. Ltd.

CIN No: U67120MH1997PTC107392